Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Regular Insulin, Humalog; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy, Subjective Cognitive Decline (SCD), Sedentary Behavior, Social Isolation in Older Adults
Interventions: Self-monitoring; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 60 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Non Functioning Entero-pancreatic Endocrine Tumour
Interventions: lanreotide (Autogel formulation); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus, Prediabetic State
Interventions: Glucose challenge test, Glucose tolerance test; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,939 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Osteoporosis, Hypercalcemia of Malignancy, Hyperparathyroidism, Bone Diseases, Endocrine
Interventions: Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 24 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cushing's Syndrome
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 20 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Gestational Diabetes
Interventions: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions: ctDNA-Guided Treatment Strategy; Device
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity, Overweight and/or Obesity, Overweight
Interventions: PF-08653944, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Canoga Park, California • Escondido, California • Modesto, California + 26 more

Conditions: Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility, Prescribing Burden
Interventions: Intervention to address diffusion of responsibility, Intervention to address diffusion of responsibility + simplification of prescribing; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 348
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more

Conditions: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 25
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions: Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer
Interventions: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Gilbert, Arizona • Burbank, California • Corona, California + 17 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: 5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel; Drug
Lead sponsor: Lakewood-Amedex Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more

Conditions: Diabetic Ketoacidosis
Interventions: Continuous Glucose Monitoring (CGM), Standard of Care; Device · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Spinal Cord Injury
Interventions: 2 hour Oral Glucose Tolerance Test, Fat Meal Test; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
Interventions: Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration, Quality-of-Life Assessment; Other · Behavioral
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 526
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more

Conditions: Gestational Diabetes, Type 2 Diabetes
Interventions: Glucose tolerance test (2 hour), Active Comparator; Diagnostic Test · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Adiposity
Interventions: Oral Glucose Tolerance Test; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Hormone Receptor-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Positron Emission Tomography, Treatment Planning, Treatment Regimen; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Search by objective public record fields.

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Increasing Physical Activity Through Social Support and Stress Resilience

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

One Week Comparison Study of PTH and PTHrP Infusions

Study of Depression, Peptides, and Steroids in Cushing's Syndrome

Islet Transplantation for Type 1 Diabetes

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Oral Testosterone for the Treatment of Hypogonadism in Males

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

A Multi-Disciplinary Technology-Based Care for Diabetic Ketoacidosis in Patients With Type 1 Diabetes

Cardiovascular Disease Study

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Preventing T2DM After GDM With Immediate Postpartum Screening

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial